Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.

[1]  J. Curtis,et al.  Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids , 2019, Arthritis Care & Research.

[2]  N. Rashid,et al.  Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. , 2019, The American journal of medicine.

[3]  P. Muntner,et al.  Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients , 2019, Arthritis care & research.

[4]  A. Grauer,et al.  Risk of subsequent fracture after prior fracture among older women , 2018, Osteoporosis International.

[5]  H. Sayles,et al.  Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival , 2018, Clinical Rheumatology.

[6]  J. Kremer,et al.  Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis , 2018, Arthritis care & research.

[7]  E. Lewis,et al.  Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study , 2017, American journal of epidemiology.

[8]  J. Curtis,et al.  Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids , 2019, Arthritis care & research.

[9]  J. Baker,et al.  Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty , 2017, Arthritis care & research.

[10]  G. Cutter,et al.  Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study , 2017, Osteoporosis International.

[11]  James R. Rogers,et al.  Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.

[12]  J. Kremer,et al.  The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights , 2017, Pharmacoepidemiology and drug safety.

[13]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[14]  P. Embí,et al.  Usability and Workflow Evaluation of “RhEumAtic Disease activitY” (READY) , 2016, Applied Clinical Informatics.

[15]  H. Sayles,et al.  Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials , 2016, Arthritis care & research.

[16]  D. Messner,et al.  Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trials , 2016, Contemporary clinical trials communications.

[17]  S. Bernatsky,et al.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments , 2016, Arthritis & rheumatology.

[18]  K. Saag,et al.  A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study , 2016, Contemporary clinical trials communications.

[19]  Soyoung Yoo,et al.  Establishing the role of honest broker: bridging the gap between protecting personal health data and clinical research efficiency , 2015, PeerJ.

[20]  J. Curtis,et al.  Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study , 2015, Arthritis Research & Therapy.

[21]  A. Schuchat.  DEPARTMENT OF HEALTH & HUMAN SERVICES , 2015 .

[22]  T. Cheetham,et al.  Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. , 2015, Mayo Clinic proceedings.

[23]  P. Donnan,et al.  The PRECIS-2 tool: designing trials that are fit for purpose , 2015, BMJ : British Medical Journal.

[24]  Shunchao Wang,et al.  High Level Architecture and Evaluation of Patient Linkages for READY - An Electronic Measurement Tool for Rheumatoid Arthritis , 2015, AMIA.

[25]  Jeffrey R Curtis,et al.  Linkage of a De‐Identified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research , 2014, Arthritis care & research.

[26]  B. Kissela,et al.  Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims , 2014, Circulation. Cardiovascular quality and outcomes.

[27]  M. Lauer,et al.  The imperative of overcoming barriers to the conduct of large, simple trials. , 2014, JAMA.

[28]  W. Winkelmayer,et al.  Comparison of Medicare Claims Versus Physician Adjudication for Identifying Stroke Outcomes in the Women’s Health Initiative , 2014, Stroke.

[29]  Ashwin Machanavajjhala,et al.  Privacy preserving interactive record linkage (PPIRL) , 2014, J. Am. Medical Informatics Assoc..

[30]  C. Maher,et al.  Recruitment rate for a clinical trial was associated with particular operational procedures and clinician characteristics. , 2014, Journal of clinical epidemiology.

[31]  Jennifer G. Robinson,et al.  Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women’s Health Initiative , 2014, Circulation. Cardiovascular quality and outcomes.

[32]  M Alan Brookhart,et al.  Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example , 2013, BMC Medical Research Methodology.

[33]  B. Yawn,et al.  The global epidemiology of herpes zoster , 2013, Neurology.

[34]  C. Stehman-Breen,et al.  Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡ , 2013, Pharmacoepidemiology and drug safety.

[35]  Gary G Bennett,et al.  Recruitment and retention of participants in a pragmatic randomized intervention trial at three community health clinics: Results and lessons learned , 2013, BMC Public Health.

[36]  J. Cauley,et al.  Magnitude and consequences of misclassification of incident hip fractures in large cohort studies: the Study of Osteoporotic Fractures and Medicare claims data , 2013, Osteoporosis International.

[37]  Amar K. Das,et al.  A simple heuristic for blindfolded record linkage , 2012, J. Am. Medical Informatics Assoc..

[38]  Suzanne L. West,et al.  Validity of Pharmacoepidemiologic Drug and Diagnosis Data , 2012 .

[39]  N. Gatto,et al.  Is the Large Simple Trial Design Used for Comparative, Post-Approval Safety Research? , 2011, Drug safety.

[40]  J. Singh,et al.  Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis , 2011, Arthritis research & therapy.

[41]  D. Moher,et al.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.

[42]  J. Kremer,et al.  Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. , 2008, The American journal of medicine.

[43]  R. D'Agostino,et al.  The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. , 2008, The Journal of clinical psychiatry.

[44]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[45]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[46]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[47]  R. Platt,et al.  The sequelae of herpes zoster. , 1997, Archives of internal medicine.

[48]  J. Manson,et al.  The incidence of herpes zoster. , 1995, Archives of internal medicine.